To enhance DDS by overcoming challenges related to safety, efficacy, and tumor penetration, Wu et al. developed EC112002, an ultrasmall FRα-targeted silica nanoparticle drug conjugate (CDC); this nanoplatforms demonstrated high specificity for FRα, efficient tumor penetration, rapid systemic clearance, and minimal off-target effects following an extensive screening of over 500 formulations. The gene discussed is FOLR1; the disease is neoplasm.